Last reviewed · How we verify

Ardeypharm GmbH — Portfolio Competitive Intelligence Brief

Ardeypharm GmbH pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
EcN-Suspension EcN-Suspension phase 3 Live biotherapeutic product Immunology / Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 shared drug class
  2. Infant Bacterial Therapeutics · 1 shared drug class
  3. Mikrobiomik Healthcare Company S.L. · 1 shared drug class
  4. OxThera · 1 shared drug class
  5. Rebiotix Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Ardeypharm GmbH:

Cite this brief

Drug Landscape (2026). Ardeypharm GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ardeypharm-gmbh. Accessed 2026-05-17.

Related